List of Excipients in Branded Drug VYONDYS 53

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sarepta Therapeutics Inc	VYONDYS 53	golodirsen	60923-465	HYDROCHLORIC ACID	2026-12-12
Sarepta Therapeutics Inc	VYONDYS 53	golodirsen	60923-465	POTASSIUM CHLORIDE	2026-12-12
Sarepta Therapeutics Inc	VYONDYS 53	golodirsen	60923-465	POTASSIUM PHOSPHATE, MONOBASIC	2026-12-12

VYONDYS 53 Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 27, 2026

VYONDYS 53 is Sarepta Therapeutics' golodirsen injection for Duchenne muscular dystrophy patients with mutations amenable to exon 53 skipping. Its formulation uses a conventional aqueous, phosphate-buffered vehicle with sodium chloride and water for injection. The main commercial opportunity is not a novel excipient platform. It is supply assurance, sterile manufacturing, container closure, stability control, and differentiated delivery for an expensive chronic oligonucleotide therapy.

The product received accelerated FDA approval on Dec. 12, 2019. Its labeled dose is 30 mg/kg administered by intravenous infusion once weekly. The product is supplied as a 100 mg/2 mL single-dose vial, equivalent to 50 mg/mL golodirsen.[1]

What is VYONDYS 53 and how is it formulated?

VYONDYS 53 contains golodirsen, a phosphorodiamidate morpholino oligomer, or PMO, designed to bind exon 53 of dystrophin pre-mRNA. The binding event promotes exon skipping and enables production of a shortened dystrophin protein in eligible patients.[1]

The formulation is a sterile aqueous injection. The labeled inactive ingredients are phosphate buffer components, sodium chloride, and water for injection. The product has a near-physiologic pH and does not depend on a lipid nanoparticle, surfactant-rich colloidal system, or biodegradable depot.

Attribute	VYONDYS 53
Active ingredient	Golodirsen
Drug class	Phosphorodiamidate morpholino oligomer
Indication	Duchenne muscular dystrophy with mutation amenable to exon 53 skipping
FDA approval	Dec. 12, 2019
Approval pathway	Accelerated approval
Dose	30 mg/kg once weekly
Administration	Intravenous infusion over approximately 30 minutes
Strength	50 mg/mL
Presentation	100 mg/2 mL single-dose vial
Primary excipient system	Phosphate-buffered aqueous solution with sodium chloride
Storage	Refrigerated storage under the FDA-approved labeling
Preservative	None indicated in the single-dose presentation

The simple excipient list does not make the product technically simple. PMO solutions require control of concentration, pH, osmolality, particulate matter, extractables and leachables, subvisible particles, and compatibility with infusion equipment.

What excipients protect VYONDYS 53?

The formulation uses four principal excipient functions:

Excipient or component	Functional role	Commercial relevance
Sodium phosphate dibasic	Buffer capacity and pH control	Requires pharmaceutical-grade sourcing and control of ionic impurities
Sodium phosphate monobasic	Buffer balance and pH control	Supports batch-to-batch pH consistency
Sodium chloride	Tonicity adjustment	Affects osmolality and infusion tolerability
Water for injection	Solvent	Requires validated sterile generation and distribution

The formulation strategy is conservative. It minimizes excipient complexity while maintaining an injectable environment for a highly charged synthetic oligonucleotide. That approach reduces the number of formulation variables but shifts risk into active pharmaceutical ingredient quality, aseptic processing, container closure, and infusion compatibility.

The product does not use a preservative in its single-dose vial. That creates a tighter sterility and handling requirement but avoids preservative exposure in a pediatric population receiving repeated intravenous treatment.

How strong is the VYONDYS 53 excipient strategy?

The excipient strategy is operationally strong but commercially narrow.

A phosphate-buffered saline-type formulation has several advantages:

1. It uses established injectable excipients with broad regulatory precedent.
2. It avoids formulation components that could complicate pediatric safety review.
3. It supports a ready-to-dilute or infusion-based administration workflow.
4. It limits the number of formulation-related failure modes.
5. It is compatible with standard sterile filling infrastructure.

The principal limitations are also clear. The product requires weekly intravenous treatment, imposes a significant infusion burden, and depends on a high-dose PMO active ingredient. Excipients do not solve the core commercial constraints of dose volume, administration frequency, renal monitoring, and infusion-center capacity.

For suppliers, the defensible opportunity is therefore less likely to be a proprietary buffer molecule. It is more likely to involve:

• Low-endotoxin phosphate and sodium chloride grades.
• High-purity water-for-injection systems.
• Single-use sterile fluid paths.
• Low-binding tubing and transfer assemblies.
• Vial and stopper systems with controlled extractables.
• Container closure systems validated for long-term refrigerated storage.
• Analytical testing for particles, osmolality, pH, concentration, and degradation products.
• Aseptic fill-finish capacity for high-value oligonucleotide injections.

What formulation patents protect VYONDYS 53?

Publicly available regulatory and company materials identify golodirsen, exon 53 skipping, and PMO chemistry as the principal protection areas. The commercial protection package is expected to combine composition-of-matter, sequence, therapeutic-use, manufacturing, and formulation claims rather than rely exclusively on the phosphate-buffered vehicle.

A conventional phosphate-buffered injectable formulation is difficult to protect broadly on excipient identity alone. Patent value is stronger where claims connect the formulation to:

• A defined golodirsen sequence or PMO backbone.
• A specific concentration range.
• A defined pH or osmolality range.
• Stability over a refrigerated shelf life.
• Reduced aggregation or particulate formation.
• A particular vial, stopper, or infusion configuration.
• Treatment of patients with genetically defined exon 53 mutations.
• Manufacturing or purification steps for the PMO drug substance.

The FDA Orange Book should be used for the live list of patents and regulatory exclusivity attached to the approved product.[2] Patent numbers and expiration dates should not be inferred from the label alone. Patent-family expiration can differ by jurisdiction, terminal disclaimer, patent-term adjustment, patent-term extension, and claim scope.

When does VYONDYS 53 lose exclusivity?

VYONDYS 53 has two separate protection questions: FDA regulatory exclusivity and patent exclusivity.

The product received orphan-drug designation and seven years of orphan-drug exclusivity from the date of approval, subject to the statutory framework and possible interruption or modification. The expected U.S. orphan-exclusivity date is Dec. 12, 2026.[1,3]

That date does not automatically create an unrestricted generic-entry opportunity. A competitor could still face unexpired patents covering golodirsen, the PMO sequence, exon-skipping treatment, manufacturing, or the approved formulation.

Protection category	VYONDYS 53 position
Orphan-drug exclusivity	Seven years from FDA approval, expected to run to Dec. 12, 2026
New chemical entity exclusivity	Not the primary protection mechanism for this product
Accelerated approval	Based on dystrophin production as a surrogate endpoint
Patent protection	Must be assessed through current USPTO, Orange Book, and patent-family records
Biosimilar exclusivity	Not applicable because golodirsen is a synthetic oligonucleotide, not a biologic
Generic pathway	Potential ANDA, 505(b)(2), or another abbreviated pathway depending on FDA comparability requirements

The FDA may approve another product for the same orphan condition during orphan exclusivity if statutory exceptions apply, including circumstances involving clinical superiority or supply limitations.[3]

What generic entry risks exist for VYONDYS 53?

The principal generic risk is not a conventional small-molecule tablet competitor. Golodirsen is a sequence-defined PMO, and the regulatory challenge involves proving pharmaceutical equivalence, sameness of active ingredient, quality comparability, and clinical relevance of any manufacturing differences.

Potential entry routes include:

ANDA risk

An ANDA applicant would need to address the active ingredient, dosage form, strength, route of administration, inactive ingredients, and bioequivalence or equivalent scientific standards. For a complex oligonucleotide injection, the FDA may apply more demanding analytical and quality expectations than for a conventional small molecule.

505(b)(2) risk

A 505(b)(2) applicant could seek approval by relying partly on FDA findings for VYONDYS 53 while introducing differences in formulation, concentration, administration, or manufacturing. A different excipient system could become a commercial differentiator, but it could also trigger additional compatibility, safety, and clinical requirements.

Patent challenge risk

A paragraph IV certification could challenge listed patents before or after orphan exclusivity expires. The most material claims would likely involve the golodirsen sequence, PMO chemistry, exon-skipping method, formulation parameters, and manufacturing process.

Which companies are challenging VYONDYS 53?

No widely established biosimilar competitor exists for VYONDYS 53. The product is not subject to the conventional biosimilar pathway used for monoclonal antibodies and other biologics.

The competitive field includes three categories:

Competitor type	Examples	Threat to VYONDYS 53
Sarepta exon-skipping products	EXONDYS 51 and AMONDYS 45	Portfolio substitution and shared infusion infrastructure
Alternative exon-skipping developers	Companies developing mutation-specific oligonucleotides	Can compete for DMD patients and payer budgets
Gene therapy developers	Micro-dystrophin and other genetic medicines	Potentially greater threat because of less frequent administration
Generic or 505(b)(2) entrants	Not established publicly as a commercial competitor	Long-term price pressure if regulatory and patent barriers fall

The largest strategic threat is not necessarily a direct golodirsen generic. It is a competing DMD therapy that reduces infusion frequency or treats a broader mutation population.

What is the FDA regulatory status of VYONDYS 53?

VYONDYS 53 has accelerated approval based on an increase in dystrophin production in skeletal muscle. The FDA required confirmatory evidence to verify clinical benefit.[1]

This status creates a regulatory risk distinct from ordinary patent risk. Failure to confirm clinical benefit can lead to labeling restrictions, additional requirements, or withdrawal proceedings. The FDA has increasingly used confirmatory-trial performance as a central issue for accelerated approvals in rare disease.

For commercial planning, the product's regulatory position should be monitored through:

• FDA approval letters and safety communications.
• Confirmatory-trial disclosures.
• Changes to the prescribing information.
• Postmarketing safety reports.
• FDA enforcement or withdrawal actions.
• Label changes affecting mutation eligibility or dosing.

What commercial opportunities exist in VYONDYS 53 excipients?

The highest-value opportunities are in enabling technologies rather than commodity excipients.

Pharmaceutical-grade raw materials

Suppliers can compete on low bioburden, low endotoxin, trace-metal control, lot consistency, and global regulatory documentation for phosphate salts and sodium chloride.

Sterile fill-finish

VYONDYS 53's single-dose injectable format creates recurring demand for validated aseptic filling, visual inspection, particulate control, vial washing, stoppering, and refrigerated distribution.

Container closure systems

The product's high-value, low-volume presentation supports premium packaging solutions. Relevant technologies include low-extractables elastomeric stoppers, coated closures, siliconization control, and vial systems that minimize adsorption and particulate generation.

Infusion-device compatibility

Because dosing is intravenous and repeated, compatibility with bags, tubing, filters, and pumps has commercial value. Low-binding materials and extractables testing can support differentiation in hospital and home-infusion settings.

Reformulation

A reduced-volume formulation, higher concentration, prefilled presentation, or subcutaneous delivery system could create substantial commercial value if it preserves exposure, tolerability, and stability. Such products may support new patent claims and lifecycle management.

Global manufacturing

Manufacturing in the United States, Europe, and Asia can reduce supply-chain concentration. The opportunity is strongest for suppliers able to provide validated, pharmacopeial-grade materials with complete change-control and comparability packages.

How does VYONDYS 53 compare with competing DMD drugs?

VYONDYS 53 competes with mutation-specific exon-skipping products and emerging gene therapies.

Product	Active modality	Mutation segment	Administration	Main commercial distinction
VYONDYS 53	Golodirsen PMO	Exon 53 amenable mutations	Weekly IV infusion	Established PMO platform and exon 53 targeting
EXONDYS 51	Eteplirsen PMO	Exon 51 amenable mutations	Weekly IV infusion	Larger addressable mutation segment
AMONDYS 45	Casimersen PMO	Exon 45 amenable mutations	Weekly IV infusion	Additional exon-skipping segment
Gene-therapy products	Viral-vector genetic medicine	Broader but product-specific eligibility	Generally one-time or infrequent dosing	Potentially lower administration burden

The PMO products share manufacturing, infusion, safety-monitoring, and payer challenges. That creates economies of scale for Sarepta but also exposes the portfolio to a common competitive weakness: chronic intravenous administration.

What revenue exposure does VYONDYS 53 create?

VYONDYS 53 is a material product within Sarepta's DMD portfolio. Public company filings have reported annual VYONDYS 53 net product revenue in the hundreds of millions of dollars, although reported revenue varies by period, gross-to-net adjustments, international sales, and portfolio mix.[4]

Revenue exposure is concentrated in:

• Continued diagnosis of exon 53-amenable patients.
• Payer coverage for high-cost chronic treatment.
• Infusion-center availability.
• Renal and safety monitoring.
• Confirmatory evidence supporting accelerated approval.
• Competition from gene therapy and other DMD modalities.
• Patent and orphan-exclusivity duration.
• Manufacturing continuity for golodirsen and sterile product.

Because the product is mutation-specific, the addressable market is smaller than the total DMD population. Its commercial value depends on high treatment persistence and premium pricing rather than broad patient penetration.

What patent litigation and settlement risks affect VYONDYS 53?

The main litigation scenarios are:

1. A paragraph IV challenge to Orange Book-listed patents.
2. A patent infringement case concerning golodirsen composition or sequence claims.
3. A dispute over exon-skipping method-of-use claims.
4. A challenge to formulation, manufacturing, or purification patents.
5. A settlement involving a licensed entry date.
6. A dispute involving patent-term adjustment, terminal disclaimers, or orphan-exclusivity interaction.

No biosimilar settlement framework applies. Any settlement would likely be structured around a generic or 505(b)(2) entry date, authorized-generic rights, licensing terms, manufacturing restrictions, or a covenant not to sue.

Key Takeaways

• VYONDYS 53 uses a conventional phosphate-buffered aqueous formulation with sodium chloride and water for injection.
• The commercial value of the excipient system lies in quality, sterility, container closure, and compatibility rather than a novel excipient.
• The expected seven-year orphan-drug exclusivity period runs from Dec. 12, 2019, to approximately Dec. 12, 2026.
• Patent risk remains separate from orphan exclusivity and requires current Orange Book and USPTO review.
• Golodirsen is a synthetic PMO, so biosimilar substitution is not the relevant competitive model.
• Generic entry may involve an ANDA, 505(b)(2), or another abbreviated pathway depending on FDA requirements.
• The strongest supplier opportunities are sterile fill-finish, high-purity excipients, low-extractables packaging, infusion compatibility, and lifecycle reformulation.
• The largest long-term commercial threat is a DMD therapy that reduces or eliminates weekly intravenous infusion.

FAQs

Can VYONDYS 53 be reformulated with a different buffer?

Potentially, but a buffer change could affect pH, osmolality, PMO stability, aggregation, infusion tolerability, container compatibility, and regulatory comparability. A reformulation could also create new patentable subject matter.

Is VYONDYS 53 eligible for biosimilar competition?

No. VYONDYS 53 contains a synthetic phosphorodiamidate morpholino oligomer rather than a biologic protein. Competition would more likely involve an abbreviated generic, 505(b)(2) product, or a different exon-skipping therapy.

Which excipient has the greatest supply-chain importance?

Water for injection and pharmaceutical-grade phosphate salts are critical, but the broader supply-chain risk is sterile fill-finish capacity. A shortage of compliant aseptic manufacturing can constrain supply even when commodity excipients are available.

Could a high-concentration VYONDYS 53 product improve commercial value?

Yes. A stable higher-concentration product could reduce infusion volume and handling time. It would require evidence that the new concentration does not increase aggregation, particulate formation, viscosity, local tolerability, or container interaction.

Does accelerated approval reduce VYONDYS 53 patent protection?

No. Accelerated approval affects the regulatory evidentiary basis and confirmatory obligations. It does not automatically shorten patent terms, although regulatory uncertainty can affect commercial forecasts and litigation strategy.

References

1. U.S. Food and Drug Administration. (2019). VYONDYS 53 (golodirsen) injection prescribing information. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
3. U.S. Food and Drug Administration. (n.d.). Orphan drug designation and exclusivity. https://www.fda.gov/industry/developing-products-rare-diseases-conditions
4. Sarepta Therapeutics, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission. https://www.sec.gov/ixviewer/ enc.